Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Certara, Inc. CERT

Healthcare  —  Health Information Services
9.11 0.22 2.47% as of 25 Sep
Market cap
$1.4B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Certara, Inc. (CERT) Business Profile

Updated before January 2025

Company Overview

Certara, Inc. (NASDAQ: CERT) is a leading provider of biosimulation software and technology-enabled services that accelerate drug discovery, development, and regulatory approval processes. Founded in 2008, Certara is headquartered in Princeton, New Jersey, USA. The company has grown significantly through strategic acquisitions and organic growth, establishing itself as a global leader in the field of biosimulation and model-informed drug development (MIDD). Certara’s leadership team includes experienced professionals from the pharmaceutical, biotechnology, and technology sectors. As of 2023, William F. Feehery serves as the Chief Executive Officer, bringing extensive expertise in life sciences and technology to the company.

Certara operates in over 60 countries, serving more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company’s mission is to optimize drug development processes, reduce costs, and improve patient outcomes through innovative biosimulation and data-driven solutions.

Core Business Segments

Certara’s business is organized into two primary segments: Software and Technology-Enabled Services.

1. Software

Certara offers a suite of biosimulation software products that enable pharmaceutical and biotechnology companies to predict drug behavior in virtual patients. Key products include:

  • Simcyp Simulator: A platform for physiologically based pharmacokinetic (PBPK) modeling, used to predict drug interactions, dosing, and safety in diverse patient populations.
  • Phoenix Platform: A comprehensive software suite for pharmacokinetic (PK) and pharmacodynamic (PD) modeling and analysis.
  • Immunogenicity and Immuno-oncology Tools: Software solutions designed to model immune responses and optimize immunotherapy development.
  • SEND Explorer: A tool for managing and analyzing nonclinical study data in compliance with the FDA’s Standard for Exchange of Nonclinical Data (SEND).

2. Technology-Enabled Services

Certara provides consulting and technology-enabled services to support drug development and regulatory submissions. Key services include:

  • Model-Informed Drug Development (MIDD): Consulting services that leverage biosimulation to optimize clinical trial design and drug development strategies.
  • Regulatory Science: Assistance with regulatory submissions, including the preparation of dossiers and responses to regulatory agencies.
  • Real-World Evidence (RWE): Services that utilize real-world data to support drug development, market access, and post-market surveillance.
  • Training and Education: Certara offers training programs to help clients maximize the value of its software and services.

Business Model

Certara operates a hybrid business model that integrates software licensing, consulting services, and training. The company generates revenue through:

  • Software Licensing: Subscription-based licensing of its biosimulation software products.
  • Consulting Services: Fees for technology-enabled services, including MIDD, regulatory science, and RWE.
  • Training Programs: Revenue from workshops, webinars, and customized training sessions.

Certara’s business model is designed to create a synergistic relationship between its software and services. By offering both, the company provides end-to-end solutions that address the complex challenges of drug development and regulatory approval.

Strategic Direction

Certara is focused on expanding its market presence and enhancing its product offerings. Key strategic initiatives include:

  • Innovation in Biosimulation: Continued investment in research and development to enhance its software capabilities and address emerging challenges in drug development.
  • Geographic Expansion: Increasing its footprint in Asia-Pacific and other high-growth markets.
  • Partnerships and Collaborations: Strengthening relationships with academic institutions, regulatory agencies, and industry partners to drive innovation and adoption of biosimulation.
  • Sustainability Goals: Implementing environmentally sustainable practices in its operations and promoting the use of biosimulation to reduce the need for animal testing.
  • New Product Categories: Exploring opportunities in adjacent markets, such as digital therapeutics and personalized medicine.

Competitive Landscape

Certara operates in a competitive market with several key players, including:

  • Schrodinger, Inc.: A provider of physics-based software for drug discovery.
  • Simulations Plus, Inc.: A competitor in the PBPK modeling and simulation space.
  • ICON plc: A global provider of clinical research and development services.
  • IQVIA Holdings Inc.: A leader in real-world evidence and data analytics for the life sciences industry.
  • Dassault Systèmes: Offers modeling and simulation solutions for various industries, including life sciences.

Certara differentiates itself through its comprehensive suite of biosimulation software, deep expertise in MIDD, and strong relationships with regulatory agencies.

Risk Factors

Certara faces several risks that could impact its business:

  • Market Dependence: The company relies heavily on the pharmaceutical and biotechnology sectors, which are subject to economic and regulatory uncertainties.
  • Regulatory Changes: Changes in regulatory requirements could affect demand for Certara’s products and services.
  • Competition: Intense competition from established players and new entrants could impact market share.
  • Supply Chain Disruptions: Although primarily a software and services company, Certara could face challenges related to data availability and infrastructure.
  • Technological Obsolescence: Rapid advancements in technology could render some of Certara’s products obsolete if the company fails to innovate.

Recent Developments

Certara has made significant strides in recent years, including:

  • Acquisitions: The acquisition of Pinnacle 21, a leader in clinical trial data standardization, to enhance its regulatory science capabilities.
  • Product Enhancements: Updates to the Simcyp Simulator and Phoenix Platform to improve usability and expand functionality.
  • Global Expansion: Opening new offices in Asia-Pacific to better serve clients in the region.
  • Collaborations: Partnering with leading academic institutions to advance biosimulation research.

Investment Considerations

Strengths:

  • Market leader in biosimulation with a strong track record of innovation.
  • Comprehensive product portfolio and integrated service offerings.
  • Established relationships with regulatory agencies and industry leaders.
  • High-margin software business with recurring revenue streams.

Risks:

  • Dependence on the pharmaceutical and biotechnology sectors.
  • Exposure to regulatory and competitive pressures.
  • Potential for technological obsolescence.

Conclusion

Certara, Inc. is well-positioned as a leader in biosimulation and model-informed drug development. With a robust product portfolio, strong industry relationships, and a focus on innovation, the company is poised for continued growth. However, investors should carefully consider the risks associated with market dependence and competition. Overall, Certara’s strategic initiatives and commitment to advancing drug development make it a compelling player in the life sciences industry.